Skip to content
value.today

Avalanche Biotechnologies, Inc.

Total raised
$199 M
4 rounds on record
Latest round
$128 M
Feb 2024
First round on record
Sep 2010
Today
Private
See the company page

Avalanche Biotechnologies, Inc. is listed today as Avalanche Biotechnologies: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Avalanche Biotechnologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2024$128 MNo. 4$50 to $250 million

Avalanche Biotechnologies, Inc.: Raise no. 4, Feb 2024

Investors in this round

20 investors had bought by the notice of Feb 21, 2024: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Avalanche Biotechnologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$128 M of $128 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$7,650,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kishor Peter Soparkar · Executive Officer
  • Laurent Fischer · Executive Officer, Director
  • Linda Rubinstein · Executive Officer
  • Setareh Gurses Seyedkazemi · Executive Officer
  • C. David Nicholson · Director
  • Dawn Gurses Svoronos · Director
  • James Gurses Scopa · Director
  • Mark Lupher · Director
  • Patrick Machado · Director
  • Rabia Gurses Ozden · Director
  • Reed Gurses Tuckson · Director
  • Scott Gurses Whitcup · Director
  • Soo Hong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in CA, NY
  • Truist Securities, Inc. (CRD 6271) · Atlanta, GeorgiaSold in CA, NY

Signed by Linda Rubinstein, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 21, 2024. Read the notice at the SEC.

equity, optionsSEC
Aug 2014$10 MNo. 3$10 to $50 million

Avalanche Biotechnologies, Inc.: Raise no. 3, Aug 2014

Investors in this round

1 investor had bought by the notice of Sep 8, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Avalanche Biotechnologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hans Hull · Executive Officer
  • Linda Bain · Executive Officer
  • Mehdi Gasmi · Executive Officer
  • Thomas Chalberg · Executive Officer, Director
  • John McLaughlin · Director
  • Mark Blumenkranz · Director
  • Paul Wachter · Director
  • Steven Schwartz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Linda Bain, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 8, 2014. Read the notice at the SEC.

equitySEC
Apr 2014$55 MNo. 2$50 to $250 million

Avalanche Biotechnologies, Inc.: Raise no. 2, Apr 2014

Investors in this round

45 investors had bought by the notice of Apr 28, 2014: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Avalanche Biotechnologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$55 M of $56 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,514,505
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas W. Chalberg · Executive Officer, Director
  • John D. McLaughlin · Director
  • Mark S. Blumenkranz · Director
  • Paul D. Wachter · Director
  • Steven D. Schwartz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC · New York, New YorkSold in CA, CT, NY

Signed by Thomas W. Chalberg, Ph.D., President & Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 28, 2014. Read the notice at the SEC.

equitySEC
Sep 2010$6 MNo. 1$2 to $10 million

Avalanche Biotechnologies, Inc.: Raise no. 1, Sep 2010

Investors in this round

16 investors had bought by the notice of Nov 26, 2013: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Avalanche Biotechnologies, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas W. Chalberg · Executive Officer, Director
  • Mark S. Blumenkranz · Director
  • Steven D. Schwarz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas W. Chalberg, Ph.D., President & Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 26, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Avalanche Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2024).

    SEC Form D · Feb 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2024

That is all the official record says: Avalanche Biotechnologies, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Avalanche Biotechnologies, Inc. are on record.

Investors#

18 named in official filings. Open an investor to see everything it has backed.

Investors in Avalanche Biotechnologies, Inc.
InvestorKindAmountRoundRoleSource
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Special Situations International Master Fund, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Hans HullPersonnot statednot statedHeld Series B preferred stock (Form 3, 2014)SEC Form 3
Mark S. BlumenkranzPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2014)SEC Form 3
Regeneron Pharmaceuticals, Inc.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Steven Daniel SchwartzPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2014)SEC Form 3
Thomas W. ChalbergPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2014)SEC Form 3
Venrock Associates VI, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Healthcare Capital Partners LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Management VI, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Partners Management VI, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Partners VI, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
VHCP Co-Investment Holdings, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
VHCP Management, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Zygtech, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 45 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Avalanche Biotechnologies, Inc.
NameRoleNamed in
Kishor Peter SoparkarExecutive officerFeb 2024
Laurent FischerExecutive officerFeb 2024
Linda RubinsteinExecutive officerFeb 2024
Setareh Gurses SeyedkazemiExecutive officerFeb 2024
Hans HullExecutive officerSep 2014
Linda BainExecutive officerSep 2014
Mehdi GasmiExecutive officerSep 2014
Thomas ChalbergExecutive officerSep 2014
Thomas W. ChalbergExecutive officerApr 2014
C. David NicholsonDirectorFeb 2024
Dawn Gurses SvoronosDirectorFeb 2024
James Gurses ScopaDirectorFeb 2024
Laurent FischerDirectorFeb 2024
Mark LupherDirectorFeb 2024
Patrick MachadoDirectorFeb 2024
Rabia Gurses OzdenDirectorFeb 2024
Reed Gurses TucksonDirectorFeb 2024
Scott Gurses WhitcupDirectorFeb 2024
Soo HongDirectorFeb 2024
John McLaughlinDirectorSep 2014
Mark BlumenkranzDirectorSep 2014
Paul WachterDirectorSep 2014
Steven SchwartzDirectorSep 2014
Thomas ChalbergDirectorSep 2014
John D. McLaughlinDirectorApr 2014
Mark S. BlumenkranzDirectorApr 2014
Paul D. WachterDirectorApr 2014
Steven D. SchwartzDirectorApr 2014
Thomas W. ChalbergDirectorApr 2014
Steven D. SchwarzDirectorNov 2013

About

American gene therapy company.